Wed, 12 Nov 2025

November 11, 2025 | News

Novartis Expands Manufacturing Footprint, Fueling Job Growth in California

Novartis, a leading global innovative medicines company, announced the opening of a new 10,000-square-foot radioligand therapy (RLT) manufacturing facility in Carlsbad, California. This state-of-the-art site represents a key milestone in the company’s previously announced $23 billion investment in US infrastructure over the next five years. The opening of the Carlsbad manufacturing facility allows Novartis to seamlessly meet future demand for RLT, adding additional capacity and augmenting the company’s world-class supply chain capabilities. The Carlsbad facility has been filed with the FDA as an additional US point of supply, and commercial manufacturing may begin once approval is granted. RLTs are a form of precision medicine that combines a tumor-targeting molecule (ligand) with a therapeutic radioisotope, enabling the delivery of radiation to the tumor with the goal of limiting damage to the surrounding cells. Because each RLT dose is custom-made and time-sensitive, with a radioactive half-life measured in hours, proximity to treatment centers and transit hubs helps ensure patients receive their treatment when and where they need it. “At Novartis, we tackle the toughest challenges in medicine by doing what’s never been done before for patients,” said Vas Narasimhan, CEO of Novartis. “Radioligand therapy is a breakthrough we’ve unlocked at scale, made possible by reimagining how innovation reaches patients. As the global leader in RLT for more than seven years, we’ve advanced this technology with a deep belief in its power to transform cancer care. The opening of our Carlsbad facility underscores our strong commitment to the US and dedication to bringing this pioneering treatment to patients across the country.” Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio, and the Carlsbad facility is its third US RLT manufacturing site, reinforcing its global leadership in radioligand therapies with unmatched expertise in development, production, and delivery to patients worldwide. The Carlsbad facility is purpose-built to manufacture the company’s FDA-approved RLTs with capacity for future expansion. “We commend Novartis for supporting our broader mission of bringing manufacturing capacity in the United States,” said FDA Commissioner Marty Makary, M.D., M.P.H.. “Our unique partnership approach is working.” “Novartis is transforming the future of cancer care—and it's happening right here in Carlsbad,” said Carlsbad City Council Member Melanie Burkholder. “This new advanced RLT production facility is a major milestone for our region, strengthening California’s position as a hub for life sciences innovation. It will bring exciting new opportunities for our community, including more engineering and manufacturing jobs. I'm proud our local community will be part of the future of cancer care.” In addition to the Carlsbad opening, Novartis has announced multiple construction initiatives and future plans in the US, including: Two additional RLT manufacturing facilities in Florida and Texas. Expansion of existing sites in Durham, North Carolina, Indianapolis, Indiana, and Millburn, New Jersey. Establishing its second global R&D hub in the US with a new state-of-the-art biomedical research innovation facility in San Diego, California. These investments, enabled by a pro-innovation policy and regulatory environment in the US, reflect Novartis' broad commitment to the market and building its infrastructure. Novartis expects to invest nearly $50 billion in its US operations over the next five years, including the $23 billion announced earlier this year, underscoring its long-term commitment to strengthening the US healthcare ecosystem.

July 05, 2023 | News

Korea's SK bioscience inks agreement on influenza research with Doherty Institute in Australia

SK bioscience, a global innovative vaccine and biotech company based in South Korea, has signed a collaboration agreement on influenza research with the Doherty Institute. The Doherty Institute is a leading biomedical research institute located in Australia, home to researchers from the Royal Melbourne Hospital and the University of Melbourne, and to one of five WHO Collaborating Centres for Reference and Research Influenza (WHOCCRRI) in the world. Under this agreement, SK bioscience and the Doherty Institute will work together to support and further research in influenza biology, vaccines, and antivirals. The programme will include testing of anti-influenza compounds to identify new antivirals, capacity building in low- and middle-incomecountries of the region and the development of a new influenza vaccine platform. SK bioscience plans to establish a proactive response system against influenza, advancing influenza vaccine R&D capability to contribute to public health on a global scale.

July 05, 2023 | News

Germany-Saudi Arabian tie up of $30 M for data-driven multiomic testing

Germany-based Centogene, the essential life science partner for data-driven answers in rare and neurodegenerative diseases, and Lifera, a biopharmaceutical company wholly-owned by the Public Investment Fund (PIF), have announced a strategic collaboration with the formation of a Joint Venture (JV) to increase local and regional access and rapid delivery of world-class multiomic testing to patients in Saudi Arabia and countries of the Gulf Cooperation Council (GCC). Under the terms of the collaboration, Centogene will receive a $30 million mandatory convertible loan from Lifera.  Centogene will provide its leading diagnostics and multiomics expertise to the JV, which together with Lifera's strong local presence and resources, will establish widespread access to local state-of-the-art genetic sequencing tailored to regional needs. The JV will build an advanced laboratory and bioinformatics infrastructure – leveraging the Centogene Biodatabank, the world's largest real-world integrated multiomic data repository in rare disease biobanks globally and neurodegenerative diseases, which has more than 70 million and over 35,000 Saudi Arabian patient datasets. The JV will develop capabilities for genetic testing and interpretation working collaboratively with Centogene globally – serving as a vehicle for large national screening and genomics programs. As such, patients in Saudi Arabia and the GCC, a rapidly growing region with over 56 million inhabitants, will have increased access to the world's most advanced and effective diagnostic offerings, which is at the core of Lifera's strategic objectives, contributing to improving national resilience and health outcomes in Saudi Arabia.

July 05, 2023 | News

Waters Corporation and Princeton University announce multi-year research collaboration

Waters Corporation has announced a multi-year research collaboration with Princeton University, in the US, that will enable scientists, faculty, and students to work together to bring their diverse skills and backgrounds to solve complex challenges in biochemistry and materials science. According to Dr Udit Batra, President and CEO, Waters Corporation, "Together our initial work will focus on improving LC-MS workflows and sample preparation to enable our customers to conduct simpler and faster analyses with even greater precision. In turn, this will help biopharma scientists deliver therapeutics that are safe and highly effective for the treatment of disease, such as oncology and autoimmune diseases." "As a leading global institution of research and teaching, Princeton welcomes collaborations with industry to enrich education and accelerate research and innovation for societal benefit," said Craig Arnold, Princeton University Vice Dean for Innovation and the Susan Dod Brown Professor of Mechanical and Aerospace Engineering. Under the new agreement, the Waters-Princeton collaboration will bring together academic and industry researchers to tap into knowledge and expertise from various scientific domains and disciplines to identify and solve problems that matter. One such research project will focus on novel media for purification to help advance drug development and discovery.

May 15, 2023 | News

Australia launches free programme for SMEs in health and medtech sector

Applications are now open for the 10-week Innovate to Grow programme, which provides SMEs with the knowledge and tools to better identify and understand their research and development (R&D) opportunities

May 15, 2023 | News

Roche launches Institute of Human Biology to accelerate breakthroughs in R&D

The IHB is expected to grow to around 250 scientists and bioengineers over the next four years.

May 05, 2023 | News

BTL To Expands North American Sales Team

To accommodate the company\'s expanding operations, BTL is also nearly doubling the size of its US headquarters in Marlborough, MA, and enhancing its internal departments to support the organization\'s growth.

April 28, 2023 | News

India\'s Healthcare Sector Sees Surge in Demand for Skilled Professionals

Jobseekers too are increasingly looking for opportunities in the healthcare segment, with a massive 52% increase in clicks for healthcare roles.

April 25, 2023 | News

Genzeon Announces Expansion with New Office in Pune to Accelerate Growth in Healthcare

This expansion also enables Genzeon to accelerate development in its Health Intelligence Platform

April 20, 2023 | News

92% of HR Leads Are Just as or More Willing to Hire Someone Laid Off-Study

A survey of more than 1,500 employees and HR pros details the truth behind layoffs and best practices for hiring and getting hired in 2023

Page 1 of 21

Featured Recruiters